https://www.nasdaq.com/press-release/abbvie-to-host-fourth-quarter-and-full-year-2021-earnings-conference-call-2022-01-05
https://www.nasdaq.com/press-release/abbvie-announces-u.s.-fda-granted-breakthrough-therapy-designation-btd-to
https://www.nasdaq.com/press-release/abbvie-to-present-at-the-40th-annual-j.p.-morgan-healthcare-conference-2022-01-04
https://www.nasdaq.com/press-release/allergan-aesthetics-completes-acquisition-of-soliton-2021-12-16
https://www.nasdaq.com/press-release/rinvoqr-upadacitinib-receives-u.s.-fda-approval-for-active-psoriatic-arthritis-2021
https://www.nasdaq.com/press-release/vuitytm-pilocarpine-hci-ophthalmic-solution-1.25-the-first-and-only-fda-approved-eye
https://www.nasdaq.com/press-release/upadacitinib-rinvoqr-achieved-primary-and-key-secondary-endpoints-in-first-phase-3
https://www.nasdaq.com/press-release/abbvie-provides-update-on-rinvoqr-upadacitinib-for-the-treatment-of-rheumatoid
https://www.nasdaq.com/press-release/abbvie-submits-application-for-risankizumab-skyrizir-in-moderate-to-severe-crohns
https://www.nasdaq.com/press-release/abbvie-to-present-at-the-evercore-isi-conference-2021-11-23
https://www.nasdaq.com/press-release/abbvie-to-present-at-the-piper-sandler-healthcare-conference-2021-11-23
https://www.nasdaq.com/press-release/allergan-aesthetics-to-present-data-from-its-leading-aesthetic-portfolio-at-the-2021
https://www.nasdaq.com/press-release/new-literature-review-highlights-economic-benefits-associated-with-achieving
https://www.nasdaq.com/press-release/abbvie-expands-immunology-portfolio-in-the-european-union-with-the-european
https://www.nasdaq.com/press-release/allergan-aesthetics-celebrates-third-annual-botoxr-cosmetic-onabotulinumtoxina-day
https://www.nasdaq.com/press-release/abbvie-university-of-chicago-extend-research-collaboration-to-support-preclinical
https://www.nasdaq.com/press-release/abbvie-to-present-at-the-wolfe-research-healthcare-conference-2021-11-10
https://www.nasdaq.com/press-release/abbvie-presents-new-efficacy-data-on-upadacitinib-rinvoqr-in-people-with-active
https://www.nasdaq.com/press-release/abbvie-to-present-new-long-term-analysis-evaluating-the-sustainability-of-response-to
https://www.nasdaq.com/press-release/allergan-an-abbvie-company-to-present-new-data-from-its-leading-eye-care-portfolio-0
https://www.nasdaq.com/press-release/abbvie-presents-integrated-efficacy-and-safety-data-from-two-phase-3-trials-on
https://www.nasdaq.com/press-release/abbvie-to-highlight-new-advances-in-blood-cancer-research-and-expanding-oncology
https://www.nasdaq.com/press-release/abbvie-highlights-innovative-research-from-its-rheumatology-portfolio-at-acr
https://www.nasdaq.com/press-release/u.s.-food-and-drug-administration-approves-vuitytm-pilocarpine-hci-ophthalmic
https://www.nasdaq.com/press-release/abbvies-cariprazine-vraylarr-met-primary-endpoint-in-phase-3-study-as-an-adjunctive
https://www.nasdaq.com/press-release/abbvie-reports-third-quarter-2021-financial-results-2021-10-29
https://www.nasdaq.com/press-release/abbvie-announces-abbv-951-foslevodopa-foscarbidopa-showed-improvement-in-controlling
https://www.nasdaq.com/press-release/allergan-an-abbvie-company-to-present-new-data-on-investigational-agn-190584-for-the
https://www.nasdaq.com/press-release/abbvie-receives-chmp-positive-opinion-for-risankizumab-skyrizir-for-the-treatment-of
https://www.nasdaq.com/press-release/allergan-aesthetics-launches-series-of-initiatives-to-support-breast-cancer-awareness
https://www.nasdaq.com/press-release/abbvies-upadacitinib-rinvoqr-met-primary-and-most-ranked-secondary-endpoints-in-phase
https://www.nasdaq.com/press-release/abbvies-rinvoqr-upadacitinib-met-primary-and-all-ranked-secondary-endpoints-in-phase
https://www.nasdaq.com/press-release/abbvie-to-host-third-quarter-2021-earnings-conference-call-2021-10-05
https://www.nasdaq.com/press-release/abbvie-to-showcase-new-data-at-the-united-european-gastroenterology-ueg-week-virtual
https://www.nasdaq.com/press-release/abbvie-presents-late-breaking-data-on-risankizumab-skyrizir-in-psoriatic-arthritis-at
https://www.nasdaq.com/press-release/abbvie-presents-new-analyses-evaluating-rinvoqr-upadacitinib-in-atopic-dermatitis
https://www.nasdaq.com/press-release/fda-approves-quliptatm-atogepant-the-first-and-only-oral-cgrp-receptor-antagonist
https://www.nasdaq.com/press-release/americans-are-frustrated-by-unexpected-blurry-near-vision-issues-a-new-survey-reveals
https://www.nasdaq.com/press-release/abbvie-presents-new-data-analyses-for-growing-dermatology-portfolio-at-the-30th
https://www.nasdaq.com/press-release/abbvie-submits-regulatory-application-to-fda-for-risankizumab-rzaa-skyrizir-for-the
https://www.nasdaq.com/press-release/abbvie-submits-regulatory-applications-to-fda-and-ema-for-upadacitinib-rinvoqr-for
https://www.nasdaq.com/press-release/abbvie-and-regenxbio-announce-eye-care-collaboration-2021-09-13
https://www.nasdaq.com/press-release/abbvie-declares-quarterly-dividend-2021-09-10
https://www.nasdaq.com/press-release/abbvie-to-highlight-its-leadership-in-movement-disorders-at-the-international
https://www.nasdaq.com/press-release/abbvie-to-present-at-the-morgan-stanley-healthcare-conference-2021-09-09
https://www.nasdaq.com/press-release/clinical-trial-of-investigational-epcoritamab-duobodyr-cd3xcd20-in-patients-with-0
https://www.nasdaq.com/press-release/clinical-trial-of-investigational-epcoritamab-duobodyr-cd3xcd20-in-patients-with-1
https://www.nasdaq.com/press-release/abbvie-to-present-data-from-its-migraine-portfolio-at-the-2021-international-headache
https://www.nasdaq.com/press-release/european-commission-approves-rinvoqr-upadacitinib-as-first-jak-inhibitor-in-the
https://www.nasdaq.com/press-release/new-england-journal-of-medicine-publishes-12-week-results-from-study-evaluating
https://www.nasdaq.com/press-release/skyrizir-risankizumab-rzaa-now-available-in-the-u.s.-as-a-single-150-mg-injection-for
https://www.nasdaq.com/press-release/jama-dermatology-publishes-data-showing-rinvoqr-upadacitinib-achieved-superiority
https://www.nasdaq.com/press-release/abbvie-reports-second-quarter-2021-financial-results-2021-07-30
https://www.nasdaq.com/press-release/fda-approves-expanded-botoxr-onabotulinumtoxina-label-to-include-eight-new-muscles-to
https://www.nasdaq.com/press-release/abbvie-and-calico-announce-second-extension-of-collaboration-focused-on-aging-and-age
https://www.nasdaq.com/press-release/new-data-presented-on-the-safety-and-efficacy-of-investigational-agn-190584-as-a
https://www.nasdaq.com/press-release/dalvancer-dalbavancin-receives-fda-approval-to-treat-acute-bacterial-skin-and-skin
https://www.nasdaq.com/press-release/venetoclax-venclextar-granted-us-fda-breakthrough-therapy-designation-btd-in-higher
https://www.nasdaq.com/press-release/allergan-an-abbvie-company-to-present-new-data-from-its-leading-eye-care-portfolio-at
https://www.nasdaq.com/press-release/abbvie-provides-update-regarding-rinvoqr-upadacitinib-for-the-treatment-of-moderate
https://www.nasdaq.com/press-release/collaboration-between-abbvie-biogen-and-pfizer-creates-worlds-largest-browsable-0
https://www.nasdaq.com/press-release/abbvie-to-host-second-quarter-2021-earnings-conference-call-2021-07-07
https://www.nasdaq.com/press-release/upadacitinib-rinvoqr-met-the-primary-and-all-secondary-endpoints-in-the-52-week-phase
https://www.nasdaq.com/press-release/abbvie-gastroenterology-pipeline-to-be-featured-at-the-16th-congress-of-european
https://www.nasdaq.com/press-release/abbvie-provides-update-regarding-rinvoqr-upadacitinib-in-psoriatic-arthritis-and
https://www.nasdaq.com/press-release/chmp-recommends-approval-of-rinvoqr-upadacitinib-for-the-treatment-of-atopic
https://www.nasdaq.com/press-release/abbvie-exercises-right-to-acquire-teneoone-and-lead-asset-tnb-383b-for-the-potential
https://www.nasdaq.com/press-release/abbvie-declares-quarterly-dividend-2021-06-17
https://www.nasdaq.com/press-release/zhongchao-inc.-partners-with-a-subsidiary-of-abbvie-inc.-nyse%3a-abbv-for-medical
https://www.nasdaq.com/press-release/imbruvicar-ibrutinib-plus-venclextar-venclyxtor-venetoclax-combination-shows-superior
https://www.nasdaq.com/press-release/new-data-shows-abbvies-venclyxtor-venclextar-fixed-duration-combination-demonstrates
https://www.nasdaq.com/press-release/caraway-therapeutics-establishes-collaboration-with-abbvie-to-develop-novel-small
https://www.nasdaq.com/press-release/allergan-aesthetics-and-botoxr-cosmetic-onabotulinumtoxina-put-real-stories-at-the
https://www.nasdaq.com/press-release/captivate-study-shows-an-imbruvicar-ibrutinib-plus-venclextar-venclyxtor-venetoclax
https://www.nasdaq.com/press-release/results-from-imbruvicar-ibrutinib-resonate-2-study-provide-up-to-seven-years-of
https://www.nasdaq.com/press-release/abbvie-to-present-at-the-goldman-sachs-42nd-annual-global-healthcare-conference-2021
https://www.nasdaq.com/press-release/phase-3-maintenance-results-show-patients-with-crohns-disease-receiving-risankizumab
https://www.nasdaq.com/press-release/abbvie-to-present-analysis-evaluating-continuous-rinvoqr-upadacitinib-treatment-in
https://www.nasdaq.com/press-release/new-long-term-efficacy-and-safety-analyses-evaluating-rinvoqr-upadacitinib-in
https://www.nasdaq.com/press-release/abbvie-to-present-at-bernsteins-37th-annual-strategic-decisions-conference-2021-05-26
https://www.nasdaq.com/press-release/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american
https://www.nasdaq.com/press-release/abbvie-showcases-the-depth-of-its-rheumatology-portfolio-with-new-data-presented-at
https://www.nasdaq.com/press-release/abbvie-receives-european-commission-approval-of-venclyxtor-venetoclax-in-combination
https://www.nasdaq.com/press-release/abbvie-presents-new-late-breaking-data-analyses-showing-risankizumab-skyrizir
https://www.nasdaq.com/press-release/the-lancet-publishes-results-from-pivotal-global-phase-3-program-evaluating-rinvoqr
https://www.nasdaq.com/press-release/abbvie-to-present-at-the-ubs-global-healthcare-virtual-conference-2021-05-20
https://www.nasdaq.com/press-release/abbvie-to-showcase-breadth-of-oncology-portfolio-and-pipeline-at-the-2021-asco-and
https://www.nasdaq.com/press-release/abbvie-to-present-at-the-rbc-capital-markets-global-healthcare-conference-2021-05-13
https://www.nasdaq.com/press-release/allergan-aesthetics-to-acquire-soliton-expanding-body-contouring-portfolio-2021-05-10
https://www.nasdaq.com/press-release/abbvie-reports-first-quarter-2021-financial-results-2021-04-30
https://www.nasdaq.com/press-release/allergan-an-abbvie-company-to-share-new-data-highlighting-latest-advancements-in-eye
https://www.nasdaq.com/press-release/abbvie-receives-positive-chmp-opinion-for-venclyxtor-venetoclax-as-a-combination
https://www.nasdaq.com/press-release/abbvie-submits-regulatory-applications-for-skyrizir-risankizumab-in-psoriatic
https://www.nasdaq.com/press-release/abbvie-to-present-data-across-its-robust-neuroscience-portfolio-at-the-2021-american
https://www.nasdaq.com/press-release/abbvie-announces-extension-of-review-for-supplemental-new-drug-application-of-0
https://www.nasdaq.com/press-release/skinmedicar-launches-neck-correct-cream-for-neck-and-decollete-2021-04-01
https://www.nasdaq.com/press-release/new-england-journal-of-medicine-publishes-24-week-results-from-phase-3-study
https://www.nasdaq.com/press-release/abbvie-to-host-first-quarter-2021-earnings-conference-call-2021-03-31
https://www.nasdaq.com/press-release/u.s.-fda-accepts-abbvies-new-drug-application-for-atogepant-for-the-preventive
https://www.nasdaq.com/press-release/abbvie-announces-extension-of-review-for-supplemental-new-drug-application-of
https://www.nasdaq.com/press-release/allergan-an-abbvie-company-submits-new-drug-application-for-investigational-agn
https://www.nasdaq.com/press-release/humirar-adalimumab-receives-fda-approval-to-treat-pediatric-patients-living-with
https://www.nasdaq.com/press-release/new-refreshr-digital-lubricant-eye-drops-tackle-eye-dryness-due-to-everyday-screen
https://www.nasdaq.com/press-release/second-phase-3-induction-study-confirms-upadacitinib-rinvoqtm-improved-clinical
https://www.nasdaq.com/press-release/abbvie-evolus-and-medytox-announce-resolution-of-intellectual-property-litigation
https://www.nasdaq.com/press-release/abbvie-to-present-at-the-cowen-41st-annual-health-care-conference-2021-02-19
https://www.nasdaq.com/press-release/abbvie-declares-quarterly-dividend-2021-02-18
https://www.nasdaq.com/press-release/abbvie-to-present-at-the-10th-annual-svb-leerink-global-healthcare-conference-2021-02
https://www.nasdaq.com/press-release/abbvie-and-caribou-biosciences-announce-collaboration-and-license-agreement-for-car-t
https://www.nasdaq.com/press-release/botoxr-onabotulinumtoxina-receives-fda-approval-for-pediatric-detrusor-overactivity
https://www.nasdaq.com/press-release/abbvie-reports-full-year-and-fourth-quarter-2020-financial-results-2021-02-03
https://www.nasdaq.com/press-release/coolsculptingr-by-allergan-aesthetics-expands-body-contouring-portfolio-with
https://www.nasdaq.com/press-release/european-commission-approves-abbvies-rinvoqtm-upadacitinib-for-the-treatment-of
https://www.nasdaq.com/press-release/allergan-aesthetics-and-allergan-an-abbvie-company-to-present-16-neurotoxin-research
https://www.nasdaq.com/press-release/allergan-aesthetics-enters-into-option-to-acquire-cypris-medical-2021-01-12
https://www.nasdaq.com/press-release/abbvie-to-host-fourth-quarter-and-full-year-2020-earnings-conference-call-2021-01-12
https://www.nasdaq.com/press-release/dragonfly-therapeutics-announces-abbvie-opt-in-of-trinkettm-immunotherapy-drug
https://www.nasdaq.com/press-release/risankizumab-skyrizir-demonstrates-significant-improvements-in-clinical-remission-and
https://www.nasdaq.com/press-release/abbvie-to-present-at-the-39th-annual-j.p.-morgan-healthcare-conference-2021-01-06
https://www.nasdaq.com/press-release/risankizumab-skyrizir-phase-3-results-demonstrate-improvements-in-disease-activity
https://www.nasdaq.com/press-release/imbruvicar-ibrutinib-u.s.-prescribing-information-updated-to-include-long-term-data
https://www.nasdaq.com/press-release/chmp-recommends-the-approvals-of-rinvoqtm-upadacitinib-for-the-treatment-of-adults
https://www.nasdaq.com/press-release/rinvoqtm-upadacitinib-achieved-superiority-versus-dupixentr-dupilumab-for-primary-and
https://www.nasdaq.com/press-release/upadacitinib-rinvoqtm-meets-primary-and-all-ranked-secondary-endpoints-in-first-phase
https://www.nasdaq.com/press-release/combined-data-from-multiple-phase-3-studies-of-imbruvicar-ibrutinib-show-efficacy-and
https://www.nasdaq.com/press-release/abbvie-presents-extended-follow-up-data-for-fixed-duration-treatment-venclextar
https://www.nasdaq.com/press-release/imbruvicar-ibrutinib-plus-venclextar-venclyxtor-venetoclax-combination-shows-high
https://www.nasdaq.com/press-release/frontier-medicines-and-abbvie-establish-global-partnership-to-discover-and-develop
https://www.nasdaq.com/press-release/abbvie-to-host-virtual-immunology-strategic-update-2020-12-01
https://www.nasdaq.com/press-release/abbvie-to-present-at-the-evercore-isi-conference-and-piper-sandler-healthcare
https://www.nasdaq.com/press-release/abbvie-announces-expiration-and-final-results-of-registered-exchange-offers-2020-11
https://www.nasdaq.com/press-release/allergan-aesthetics-celebrates-second-annual-botoxr-cosmetic-onabotulinumtoxina-day
https://www.nasdaq.com/press-release/abbvie-to-present-at-the-wolfe-research-healthcare-conference-2020-11-12
https://www.nasdaq.com/press-release/abbvie-to-highlight-blood-cancer-leadership-and-advancing-oncology-pipeline-at-the
https://www.nasdaq.com/press-release/abbvie-reports-third-quarter-2020-financial-results-2020-10-30
https://www.nasdaq.com/press-release/abbvie-to-present-new-analyses-from-pivotal-phase-3-studies-for-rinvoqtm-upadacitinib
https://www.nasdaq.com/press-release/abbvie-highlights-innovative-research-for-people-with-rheumatic-diseases-with-new
https://www.nasdaq.com/press-release/allergan-an-abbvie-company-announces-positive-phase-3-topline-results-for
https://www.nasdaq.com/press-release/abbvie-submits-regulatory-applications-to-fda-and-ema-for-rinvoqtm-upadacitinib-in
https://www.nasdaq.com/press-release/abbvie-announces-commencement-of-registered-exchange-offers-2020-10-19
https://www.nasdaq.com/press-release/venclextar-venetoclax-receives-fda-full-approval-for-acute-myeloid-leukemia-aml-2020
https://www.nasdaq.com/press-release/allergan-aesthetics-to-present-data-from-4-abstracts-at-the-2020-american-society-for
https://www.nasdaq.com/press-release/allergan-aesthetics-an-abbvie-company-acquires-innovative-luminera-dermal-filler
https://www.nasdaq.com/press-release/abbvie-to-host-third-quarter-2020-earnings-conference-call-2020-10-06
https://www.nasdaq.com/press-release/abbvie-to-present-new-data-from-15-abstracts-at-the-2020-virtual-migraine-trust
https://www.nasdaq.com/press-release/abbvie-receives-orphan-drug-and-fast-track-designations-from-the-u.s.-food-and-drug
https://www.nasdaq.com/press-release/malin-akerman-joins-coolsculptingr-and-cooltonetm-as-u.s.-ambassador-for-the-allergan
https://www.nasdaq.com/press-release/allergan-aesthetics-and-skinbetter-science-announce-the-dream-initiativetm-to-advance
https://www.nasdaq.com/press-release/abbvie-to-present-new-data-from-18-abstracts-at-the-international-congress-of
https://www.nasdaq.com/press-release/abbvie-declares-quarterly-dividend-2020-09-11
https://www.nasdaq.com/press-release/abbvie-and-i-mab-enter-into-global-strategic-partnership-for-differentiated-immuno-0
https://www.nasdaq.com/press-release/abbvie-to-present-at-the-morgan-stanley-healthcare-conference-2020-09-03
https://www.nasdaq.com/press-release/abbvie-submits-regulatory-application-to-fda-for-rinvoqtm-upadacitinib-for-the
https://www.nasdaq.com/press-release/abbvie-harvard-university-form-research-alliance-to-address-emergent-viral-diseases
https://www.nasdaq.com/press-release/morphic-announces-that-abbvie-exercises-license-option-to-avb6-integrin-inhibitor
https://www.nasdaq.com/press-release/new-england-journal-of-medicine-publishes-positive-phase-3-data-of-venetoclax
https://www.nasdaq.com/press-release/members-of-the-covid-rd-alliance-and-quantum-leap-healthcare-collaborative-enroll
https://www.nasdaq.com/press-release/abbvie-reports-second-quarter-2020-financial-results-2020-07-31
https://www.nasdaq.com/press-release/abbvie-announces-positive-phase-3-data-for-atogepant-in-migraine-prevention-2020-07
https://www.nasdaq.com/press-release/third-pivotal-phase-3-study-shows-rinvoqtm-upadacitinib-plus-topical-corticosteroids
https://www.nasdaq.com/press-release/rinvoqtm-upadacitinib-monotherapy-meets-all-primary-and-secondary-endpoints-in-second
https://www.nasdaq.com/press-release/fda-approves-expanded-botoxr-onabotulinumtoxina-label-for-the-treatment-of-pediatric
https://www.nasdaq.com/press-release/abbvie-to-host-second-quarter-2020-earnings-conference-call-2020-07-07
https://www.nasdaq.com/press-release/abbvie-to-host-fourth-quarter-and-full-year-2019-earnings-conference-call-2020-01-13
https://www.nasdaq.com/press-release/abbvie-announces-leadership-team-and-creation-of-new-business-allergan-aesthetics
https://www.nasdaq.com/press-release/abbvie-to-present-at-the-38th-annual-j.p.-morgan-healthcare-conference-2020-01-03
https://www.nasdaq.com/press-release/abbvie-and-scripps-research-announce-collaboration-to-develop-a-broad-range-of-new
https://www.nasdaq.com/press-release/more-than-seven-year-analysis-of-early-treatment-with-imbruvicar-ibrutinib
https://www.nasdaq.com/press-release/imbruvicar-ibrutinib-plus-venclextar-venclyxtor-venetoclax-combination-data-show-high
https://www.nasdaq.com/press-release/abbvie-to-present-latest-clinical-research-in-the-treatment-of-leukemias-lymphomas
https://www.nasdaq.com/press-release/harpoon-therapeutics-and-abbvie-announce-licensing-and-option-collaboration-to
https://www.nasdaq.com/press-release/dragonfly-therapeutics-announces-collaboration-with-abbvie-for-autoimmune-diseases
https://www.nasdaq.com/press-release/abbvie-announces-extension-of-expiration-date-for-exchange-offers-for-allergan-notes
https://www.nasdaq.com/press-release/abbvie-prices-%2430-billion-of-senior-unsecured-notes-2019-11-13
https://www.nasdaq.com/press-release/new-positive-data-for-rinvoqtm-upadacitinib-on-signs-and-symptoms-in-patients-with
https://www.nasdaq.com/press-release/abbvie-submits-supplemental-new-drug-application-to-u.s.-fda-for-imbruvicar-ibrutinib
https://www.nasdaq.com/press-release/abbvie-announces-results-of-early-participation-in-exchange-offers-and-consent
https://www.nasdaq.com/press-release/abbvie-announces-launch-of-private-offering-of-senior-unsecured-notes-2019-11-06
https://www.nasdaq.com/press-release/thinking-about-buying-stock-in-abbvie-agile-therapeutics-intel-peloton-interactive-or
https://www.nasdaq.com/press-release/abbvie-to-showcase-depth-of-immunology-portfolio-and-pipeline-at-the-2019-acr-arp
https://www.nasdaq.com/press-release/abbvie-reports-third-quarter-2019-financial-results-2019-11-01
https://www.nasdaq.com/press-release/abbvie-launches-let-me-be-clear-to-empower-people-with-psoriasis-to-speak-up-and-seek
https://www.nasdaq.com/press-release/abbvie-announces-commencement-of-exchange-offers-and-consent-solicitations-for-2
https://www.nasdaq.com/press-release/abbvie-to-present-at-the-wolfe-research-inaugural-healthcare-conference-2019-10-24
https://www.nasdaq.com/press-release/abbvie-announces-collaboration-with-cystic-fibrosis-foundation-2019-10-24
https://www.nasdaq.com/press-release/abbvie-receives-chmp-positive-opinion-for-upadacitinib-rinvoqtm-for-the-treatment-of
https://www.nasdaq.com/press-release/latin-american-countries-offer-unique-benefits-cannabis-cultivators-2019-04-21
https://www.nasdaq.com/press-release/abbvie-announces-call-entries-abbvie-cf-scholarship-2019-2020-academic-school-year
https://www.nasdaq.com/press-release/morphosys-nominates-new-candidate-supervisory-board-2019-04-21
https://www.nasdaq.com/press-release/alector-initiates-phase-1-trial-al003-treatment-patients-alzheimers-disease-2019-04
https://www.nasdaq.com/press-release/abbvie-announces-first-regulatory-approval-skyrizitm-risankizumab-treatment-plaque
https://www.nasdaq.com/press-release/abbvie-donates-40-million-rebuild-north-chicago-middle-school-2019-04-21
